VantAI
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
116 E 16th St Fl 12, New York City, New ...Phone Number
+54 3424695740Website
www.vant.aiRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About VantAI
VantAI is a company focused on generative AI-enabled drug discovery, aiming to revolutionize medicine by making protein interactions programmable. They offer an integrated discovery platform with technologies for inducers, modulators, and blockers, particularly highlighted by the launch of Neo-1, the first AI model for therapeutic design. The company works in collaboration with industry leaders such as Blueprint Medicines to advance induced proximity drug discovery. VantAI seeks to attract professionals who are eager to tackle complex scientific challenges through innovative AI applications.Explore more
VantAI Org Chart
AP
Associate Director
GS
Senior HR Business Partner
XB
ServiceNow Developer
DA
Machine Learning Engineer
DF
Computational Biologist Ii
LF
Computational Chemist
AS
Computational Chemist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VantAI your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on VantAI recently announced quarterly report
Click to see if VantAI had a recent Job posting/layoffs
Funding: Get notified immidiatlly once VantAI has new funding data
Congratulate Masked Content for being promoted to Masked Content at VantAI
Product Launch: Get notified when VantAI launches new products
Website visits: Recent activity has been detected on your website
Check out if VantAI is spiking on competitors!
Check if VantAI has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
VantAI, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at VantAI
Find 2 more new buyers
Compare Similar Companies to VantAI
Compare insights from companies similar to VantAI, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
VantAI is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
VantAI is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about VantAI.
VantAI Tech Stack
A closer look at the technologies used by VantAI
Most Recent Scoops
Open Position
Open Position
Open Position
Event
Cloud, Product Marketing, Events, Infrastructure, Engineering, Clinical Systems, Data Management, Data Science, Machine Learning, Sales, Enterprise Software, Software, Bioengineering, Pharmaceuticals, Field /Outside Sales, Artificial Intelligence, Clinical Operations, Field Marketing, Healthcare Technology, Operations
Open Position
VantAI News & Media
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreement with Blueprint Medicines, a global biopharmaceutical company, to prioritize targets and design and advance novel therapies for areas of high medical need. This new amendment further expands the companies’ successful 2022 collaboration by including additional drug target programs, and further undVantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI today unveiled Neo-1, the world’s most advanced atomistic foundation model and the first to unify de novo molecular generation with multimodal structure prediction, at NVIDIA GTC 2025. Neo-1 is designed to make the systematic re-wiring of protein interactions possible, enabling drug developers to precision-engineer novel therapeutics, including molecular glues, bifunctional degraders, and other proximity-based modalities. For an expanded technical preview,VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AI
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AIVantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery
VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VantAI
Sign Up For FreeTo access detailed company insights
VantAI is a company focused on generative AI-enabled drug discovery, aiming to revolutionize medicine by making protein interactions programmable. They offer an integrated discovery platform with technologies for inducers, modulators, and blockers, particularly highlighted by the launch of Neo-1, the first AI model for therapeutic design. The compa... Read More
